Drugs are delivered to cancer cells by inhibition of the solute carrier (SLC) family, which also leads to multidrug resistance (MDR) development in HCC cells (Lei et al., 2024), chemotherapeutic medications typically have little effect on HCC patients. This evidence concerns the gene CCL21 and hepatocellular carcinoma.